2018 Dilated Cardiomyopathy Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Dilated Cardiomyopathy Market

June 2018 | 70 pages | ID: 25FEC5FADEFEN
VPAResearch

Abstracts

Dilated cardiomyopathy is a heart related disease in which the left ventricle enlarges and thereby becomes thin. This results in reduce efficiency of the heart to do its regular pumping activity. It is a progressive disease and affects around 5 million population in the US and Europe. The mortality rate is also high with an estimated 10,000 deaths in the US. It is considered as the primary reason for heart transplantation and use of cardiac support equipment.

To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Dilated Cardiomyopathy pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Dilated Cardiomyopathy pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Dilated Cardiomyopathy pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 List of LIST OF FIGURES
1.2 List of Tables

2 DILATED CARDIOMYOPATHY PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview
2.2 Dilated Cardiomyopathy Pipeline Snapshot
2.3 Dilated Cardiomyopathy Pipeline by Phase
2.4 Dilated Cardiomyopathy Pipeline by Company
2.5 Dilated Cardiomyopathy Pipeline by Mechanism of Action

3 DILATED CARDIOMYOPATHY- COMPANY WISE PIPELINE ANALYSIS

Adrenergics, Inc.
Array BioPharma
Berlin Cures GmbH
Capricor Therapeutics Inc
MyoKardia Inc
Sanofi SA
Vericel Corp

4 DILATED CARDIOMYOPATHY R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN DILATED CARDIOMYOPATHY PIPELINE

6 APPENDIX

6.1 About VPA Research
6.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Dilated Cardiomyopathy Pipeline by Phase, H2- 2018
Figure 2: Dilated Cardiomyopathy Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Dilated Cardiomyopathy Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018

List Of Tables

LIST OF TABLES

Dilated Cardiomyopathy Pipeline by Phase, H2- 2018
Dilated Cardiomyopathy Pipeline by Companies, H2- 2018
Dilated Cardiomyopathy Pipeline by Mechanism of Action, H2- 2018
Table 1: Adrenergics, Inc. Dilated Cardiomyopathy Pipeline Drugs, H2- 2018
Table 2: Array BioPharma Dilated Cardiomyopathy Pipeline Drugs, H2- 2018
Table 3: Berlin Cures GmbH Dilated Cardiomyopathy Pipeline Drugs, H2- 2018
Table 4: Capricor Therapeutics Inc Dilated Cardiomyopathy Pipeline Drugs, H2- 2018
Table 5: MyoKardia In Dilated Cardiomyopathy Pipeline Drugs, H2- 2018
Table 6: Sanofi SA Dilated Cardiomyopathy Pipeline Drugs, H2- 2018
Table 7: Vericel Corp Dilated Cardiomyopathy Pipeline Drugs, H2- 2018